RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc. has announced that it has filed a provisional composition of matter patent application with the U.S. Patent and Trademark Office entitled, “Stable, Buffer-free Compositions of Vasoactive Intestinal Peptide.”
January 4, 2022
· 4 min read